Brightpath Biotherapeutics Co.ltd. · TSE:4594

Brightpath Biotherapeutics Co.ltd — Investor Presentation (May 2024)

25 slides from Brightpath Biotherapeutics Co.ltd's investor presentation, May 21, 2024

  1. Slide 1: Corporate Presentation

    Corporate Presentation May 21, 2024 Copyright © BrightPath Biotherapeutics Co., Ltd. Copyright © BrightPath Biotherapeutics Co., Ltd.

  2. Slide 2: Disclaimer

    Disclaimer The material that follows is a presentation of general background information about BrightPath Biotherapeutics Co., Ltd. (“BrightPath”) as of the date of this presentation. This material prepared solely for information purpose and is not to be construed as a solicitation or an offer to bu

  3. Slide 3: BrightPath Bio (Tokyo Stock Exchange Growth 4594)

    BrightPath Bio (Tokyo Stock Exchange Growth 4594)  BrightPath Bio is a clinical-stage biopharmaceutical company focused on developing immuno-oncology products  Three focused modalities: cell therapy, immune modulatory antibody, and cancer vaccine  BP2202 is a novel platform of allogeneic CAR-T ce

  4. Slide 4: Cell Therapy

    Cell Therapy BrightPath_ Eee:

  5. Slide 5: BP2201 (Unmodified iPS-NKT Cell)

    BP2201 (Unmodified iPS-NKT Cell) FY2023 Highlights  The first-in-human Phase I study of the iPS cell-derived NKT cells was conducted in patients with r/r HNSCC under the primary endpoint of tolerability and safety  Some patients at high-dose experienced some level of tendency of tumor shrinkage, w

  6. Slide 6: BP2202 (CAR-iPSNKT)

    BP2202 (CAR-iPSNKT) A Novel Allogenic CAR-T Platform  Invariant natural killer T (iNKT) cell is a rare subset of T lymphocytes that has not only direct but indirect anti-tumor activity by priming CD8+ T cells and other immune cells  Allogeneic CAR-transduced iPSC-derived iNKT cells retain the naïv

  7. Slide 7: BP2202 (CAR-iPSNKT) (cont'd)

    BP2202 (CAR-iPSNKT) (cont’d) iNKT cells induce host endogenous CD8+T with memory phenotype, which is expected to provide durability of clinical responses allo NKT alo αβT allo γδT allo NK Innate - adaptive immunity bridging DC cross-talking ✓ Possible source of CD8+ T cross-priming ✓ durability Myel

  8. Slide 8: BP2202 (CAR-iPSNKT) (cont'd)

    BP2202 (CAR-iPSNKT) (cont’d) Prototype HER2-CAR iNKT cells showed target-specific anti tumor effects  Cytotoxic activity (A) and Cytokine secretion (B)  Tumor burden of SK-OV-3-luc bearing mice (A), Spider plot (HER-2 expressing tumor cell line SK-OV-3) of total flux and body weight ratio (B) and

  9. Slide 9: BP2202 (CAR-iPSNKT) (cont'd)

    BP2202 (CAR-iPSNKT) (cont’d) Landscape of iPS-NK/NKT platform company Target (IND filing year) Blood Cancer CAR Solid Tumor unmodified Multiple CAR Company unmodified Lymphoma Leukemia Collaborations Myeloma (Platform type licensee) iPS-T HER2 (2023) 2018 (2 Targets) 2018 CD19 (2023) 2021(Multiple T

  10. Slide 10: BP2301 (HER2 CAR-T)

    BP2301 (HER2 CAR-T) Autologous, non-virally CAR transduced, HER2-targeting CAR-T cells • T cell differentiation and phenotypes  Stem cell memory-like T (TSCM) phenotype-rich CAR-T cells, mediated by the non-viral piggyBac transposon system for CAR transduction  TSCM effector exhibiting continuous

  11. Slide 11: BP2301 (HER2 CAR-T) (cont'd)

    BP2301 (HER2 CAR-T) (cont’d)  PiggyBac-mediated, TSCM-rich BP2301 demonstrated potent and sustained killing activity  BP2301 showed persistent cytotoxicity against  BP2301 eradicated inoculated tumor in an ovarian HER2+ sarcoma in a serial killing assay Data cancer xenograft model Target Cells: U

  12. Slide 12: Antibody Pipelines

    Antibody 01 Pipelines 11

  13. Slide 13: BP1202 (anti-CD39 Antibody)

    BP1202 (anti-CD39 Antibody)  A Novel Strategy on Targeting CD39 Rediscovery of CD39 as a target for depleting cancer cells and Tregs, while avoiding adenosine generation in the tumor microenvironment  The conventional strategy to inhibit adenosine generation hasn't yielded promising results thus f

  14. Slide 14: BP1202 (anti-CD39 Antibody)(cont'd)

    BP1202 (anti-CD39 Antibody)(cont’d) Direct Killing Treg depletion  BP1202-NF2, of which glycosylation is opti-  BP1202-NF2 demonstrated high ADCC activity  CD39 expression was elevated on tumor-infiltrating Tregs mized by CD39 density, affinity to CD39, and against Treg and exhausted CD8+T cells

  15. Slide 15: BP1212 (anti-CD39 x anti-TIM3 Bispecific Antibody)

    BP1212 (anti-CD39 x anti-TIM3 Bispecific Antibody) First-in-class Dual Blockade of CD39 and TIM-3 Blockade of redefined immune checkpoints where it’s meant to function by targeting two pathways  CD39 is well known as an intervening enzyme for adenosine generation and Tim-3 is recognized as a T-cell

  16. Slide 16: BP1212 (anti-CD39 x anti-TIM3 Bispecific Antibody) (cont'd)

    BP1212 (anti-CD39 x anti-TIM3 Bispecific Antibody) (cont’d) CD39 inhibition Inhibition of TIM-3  BP1212 preferentially binds  Inhibition of CD39 is enhanced on  Inhibition of PtdSr binding to TIM3+ CD39+ cells by the TIM3+ CD39+ cells higher affinity and avidity Affinity isotype ctl 15,000 100 +

  17. Slide 17: BP1210 (anti-TIM3 Antibody)

    BP1210 (anti-TIM3 Antibody) A Novel TIM-3 Targeting Strategy: Blocking the Binding of All Ligands  Increasing expression of Tim-3 and Galectin-9, one of the four known ligands of Tim-3, are reported to relevant to poor prognosis cancers such as pancreatic carcinoma, glioma, cervical carcinoma, lymp

  18. Slide 18: BP1210 (anti-TIM3 Antibody) (cont'd)

    BP1210 (anti-TIM3 Antibody) (cont’d) A novel humanized, IgG1-Fc silent biparatopic antibody  BP1210 binds to two distinct TIM-3 epitopes: one is the same Binging Affinity Enhancement domain as sabatolimab (Novartis) and all other Abs advanced in  Biparatopic antibody clinical development, and the

  19. Slide 19: BP1200 (anti-CD73 Antibody)

    BP1200 (anti-CD73 Antibody)  Novel anti-CD73 antibody taking standard strategy of adenosine generation blockade with a best- in-class profile  Attenuates the activity of CD73 as a non-competitive inhibitor without hook effect Enzyme inhibition  Enhances the proliferation, cytotoxicity, and cytoki

  20. Slide 20: Cancer Vaccine Pipeline

    Cancer 01 Vaccine Pipeline 19

  21. Slide 21: BP1209 (Fully Personalized Neoantigen Vaccine)

    BP1209 (Fully Personalized Neoantigen Vaccine) A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies  The BP1209 vaccine is delivered as a molecular complex of patient-specific neoantigen peptides and immune-checkpoint inhibitor antibody such as anti-

  22. Slide 22: BP1209 (Fully Personalized Neoantigen Vaccine) (cont'd)

    BP1209 (Fully Personalized Neoantigen Vaccine) (cont’d)  BP1209 exerted robust anti-tumor effect in  BP1209 strongly enhances stem-like Tex infiltration therapeutic setting into tumor • Atezolizumab conjugated BP1209 vaccine maintained • Mice treated with the BP1209 vaccine marked increase complet

  23. Slide 23: Company Profile

    Company Profile BrightPath_ Eee:

  24. Slide 24: Company Profile

    Company Profile BrightPath Biotherapeutics Co., Ltd. (Tokyo Stock Exchange Growth: 4594) Business Development of novel cancer immunotherapy Foundation May 2003 Listing November 2015 Employees 24 (as of March 2024) Headquarters: 2-2-4 Kojimachi, Chiyoda-ku, Tokyo Location Research Laboratories: 3-25-

  25. Slide 25: Copyright © BrightPath Biotherapeutics Co., Ltd.

    Copyright © BrightPath Biotherapeutics Co., Ltd.

BrightPath Biotherapeutics — Investor Presentation (May 2024) on 6ix